A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225

Study Overview

The purpose of this study is to test any good and bad effects of the study drug called pembrolizumab when it is given in combination with Y90 (TheraSphere?).

Study Description

The purpose of this study is to evaluate the efficacy as well as the safety of combining pembrolizumab with Yttrium-90 radioembolization in subjects with poor prognosis hepatocellular carcinoma not eligible for liver transplant or surgical resection with well compensated liver function.

Additional Information

Participants will not be paid for their participation.


  • IRB Number: 1706864763 (GI15-225)
  • Research Study Identifier: TX8124
  • Principal Investigator: Paul Helft, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176